Safety and Efficacy of Anti-Fungal agents in Cholangiocarcinoma Patients: A Multi-Center Retrospective Case-Controlled Study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Comorbid conditions in cancer patients arising from coinfections are one of the main risks of mortality. Recurrent infections are well-known for reducing quality of life in cancer patients. Long-term efficacy of anti-fungal and anti-bacterial agents for drug repositioning is of great importance. In this longitudinal study long term risk and benefits of anti-fungal plus anti-bacterial agents are compared to anti-bacterial agents.
Methods
In this multi-center study, patients (n = 3048) diagnosed with cholangiocarcinoma from 1 st January 2010 to 1 st January 2021 at Severance hospital were analyzed. All patients (n = 983) received standard therapy were included, post propensity score matching (n = 153) patients were included in arm-A treated with anti-bacterial plus anti-fungal agents and (n = 153) in arm-B treated with anti-bacterial agents. Using cox-proportional hazard model, and random forest analyses, efficacy of antimicrobials prescribed during cancer treatment. Post-chemotherapy and post-diagnosis survival in infected were compared among groups. Lastly post infection end-stage leukopenia and leukocytosis events 30 days prior to death were compared.
Results
In this study total (n = 306) cholangiocarcinoma patients were included post propensity score matching. There is no significant difference in mean days survived post-cancer diagnosis 712 days (95% CI 605 – 818) arm-A and 615 days (95% CI 536 – 693) survived by arm-B with ( p -value 0.15). During chemotherapy antibiotic treated arm-A patients survived mean 896 days (95% CI 568 - 1223) compared to arm-B 622 days (95% CI 501 - 742) with p -value 0.05. Significant statistical difference in end-stage mortality caused by chemotherapy induced co-infection and leukopenia were found higher in arm-A (14%) compared to arm-B (3%) with ( p -value 0.05). Post exposure to anti-fungals hazard ratio of fluconazole (n = 113) users compared to non-users (n = 40) of arm-A patients were 1.391 (0.994 – 1.949) with p -value 0.07. Hazard ratio of arm-A fluconazole user Vs arm-B teicoplanin treated patients were 1.027 (0.763 – 1.384) with p -value 0.8.
Conclusion
Patients co-treated with anti-bacterial and anti-fungal agents during chemotherapy survived significantly longer compared to patients treated with anti-bacterial agents alone. Co-treated patients experienced more leukopenia than patients treated with anti-bacterial drugs 8 days prior to death. Mortalities post fluconazole or teicoplanin exposure suggested end-stage fungal or bacterial infections were fatal.
